Challenges and rewards of spinning out research
Published on 9 July 2014
BioVex, the company founded by former UCL Professor David S Latchman was sold to Amgen in 2011 for $1 billion; making it one of the biggest buyouts of a UK biotech company.
In the Times Higher Education this week, he outlines the challenges and rewards of spinning out his research, and his tips and advice for those who want to undertake the same journey.
About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. UCLB supports UCL’s Grand Challenges of increasing UCL’s positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit www.uclb.com.Print friendly version of Challenges and rewards of spinning out research